Comparative Pharmacology
Head-to-head clinical analysis: LUMATEPERONE TOSYLATE versus PALIPERIDONE PALMITATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMATEPERONE TOSYLATE versus PALIPERIDONE PALMITATE.
LUMATEPERONE TOSYLATE vs PALIPERIDONE PALMITATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lumateperone tosylate is an atypical antipsychotic with a unique mechanism of action involving antagonism of serotonin 5-HT2A receptors, partial agonism of serotonin 5-HT1A receptors, and antagonism of dopamine D2 receptors; it also modulates glutamate via phosphorylation of GluN2B subunits and inhibits serotonin reuptake.
Paliperidone is an atypical antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors. It also blocks alpha-2 adrenergic and H1 histaminergic receptors.
42 mg orally once daily
Paliperidone palmitate is administered intramuscularly. Initial dose: 150 mg eq. on day 1 and 100 mg eq. on day 8, both in the deltoid muscle. Maintenance dose: 75 mg eq. monthly (range 25–150 mg eq.) administered in the deltoid or gluteal muscle.
None Documented
None Documented
Terminal elimination half-life is approximately 24-29 hours, allowing once-daily dosing. Steady-state reached in about 5 days.
Terminal elimination half-life: 25-49 days (mean ~30 days) for IM injection; allows monthly dosing
Approximately 60% excreted in urine as metabolites (unchanged drug negligible) and 30% in feces via biliary elimination.
Renal: 80% as unchanged drug and metabolites; fecal: 11%
Category C
Category A/B
Atypical Antipsychotic
Atypical Antipsychotic